Low dose Ara-C for myelodysplastic syndromes: Is it still a current therapy?

Leukemia and Lymphoma

Volumn 45, Issue 8, 2004, Pages 1531-1538

  Visani, Giuseppe ^a   Malagola, Michele ^b   Piccaluga, Pier Paolo ^b   Isidori, Alessandro ^b  

^a H San Salvatore ^*  (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cytosine arabinoside; Growth factors; Low dose therapy; Myelodysplastic syndromes

Indexed keywords

ACLARUBICIN; COLONY STIMULATING FACTOR 1; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; CYTOTOXIC AGENT; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; ISOTRETINOIN; THYMOPOIETIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; BLEEDING; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DRUG APPROVAL; DRUG INDICATION; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; GROUPS BY AGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY; HUMAN; INFECTION; LEUKEMOGENESIS; LOW DRUG DOSE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 3042733132     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001653727     Document Type: Review

References (43)

1. Greenberg, P.L., Young, N.S. and Gattermann, N. (2002) "Myelodisplastic Syndromes", Hematology 2002, (Am. Soc. Hematol. Educ. Program), 136-161.
2. Hellstrom-Lindberg, E., Willman, C., Barrett, A.J. and Saunthararajah, Y. (2000) "Achievement in understanding and treatment of Myelodysplastic Syndromes", Hematology 2000 (Am. Soc. Hematol. Educ. Program), 110-132.
3. Alessandrino, E.P., Amadori, S., Cazzola, M., Locatelli, F., Mecucci, C., Morra, E., et al. (2001) "Myelodysplastic syndromes: recent advances", Haematologica, 86, 1124-1157.
4. Reskind, W.H., Steinmann, L. and Najfeld, V. (1998) "Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer", Leukemia, 12, 128-135.
5. Bennett, J.M., Catowsky, D. and Daniel, M.T. (1982) . "The French-American-British (FAB) cooperative group proposal for the classification of the myelodysplastic syndromes", Br. J. Haematol., 51, 189-199.
6. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., et al. (1999) "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997", J. Clin. Oncol., 17, 3835-3849.
7. Alessandrino, E.P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L.N., et al. (2002) "Evidence- and consensus-based guidelines for the therapy of primari myelodysplastic syndromes. A statement from the Italian Society of Hematology", Haematologica, 87, 1286-1306.
8. Sierra, J., Perez, W.S., Rozman, C., Carreras, E., Klein, J.P., Rizzo, J.D., et al. (2002) "Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia", Blood, 100(6), 1997-2004.
9. Beran, M. (2000) "Intensive chemotherapy for patients with high-risk myelodysplastic syndrome", Int. J. Hematol., 72(2), 139-150.
10. Seng, J.E. and Peterson, B.A. (1998) "Low dose chemotherapy for myelodysplastic syndromes", Leuk. Res., 22, 481-484.
11. Sachs, I. (1978) " The differentiation of myeloid leukaemia cells: new possibilities for therapy". Br. J. Haematol., 40, 509-513.
12. Griffin, J., Munroe, D., Major, P. and Kufe, D. (1982) "Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis", Exp. Hematol., 10, 774-779.
13. Cheson, B.D., Jasperse, D.M., Simon, R. and Friedman, MA. (1986) "A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes" J. Clin. Oncol., 4(12), 1857-1864.
14. Koeffler, H.P. (1983) "Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implications", Blood, 62(4), 709-721.
15. Baccarani, M. and Tura, S. (1979) "Differentiation of myeloid leukemic cells: new possibilities for therapy", Brit. J. Haematol., 42(3), 485-487.
16. Wisch, J.S., Griffin, J.D. and Kufe, D.W. (1983) "Response of preleukemic syndromes to continous infusion of low-dose cytarabine", New Engl. J. Med., 309, 1599.
17. Aul, C. and Gatterman, N. (1992) "The role of low-dose chemotherapy in myelodisplastic syndromes", Leak. Res., 16(3), 207-215.
18. Baccarani, M., Zaccaria, A., Bandini, G., Cavazzini, G., Fanin, R. and Tura, S. "Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia", Leuk. Res., 7(4), 539-545.
19. Mufti, G.J, Oscier, D.G., Hamblin, T.J., Copplestone, A. and Abidi, S.M. (1984) "Cytarabine in pre-leukemia", Lancet, 1(8387), 1187.
20. Tricot, G., De Bock, R., Dekker, A.W., Boogaerts, M.A., Peetermans, M., Punt, K., et al. (1984) "Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes", Brit. J. Haematol., 58(2), 231-240.
21. Alessandrino, E.P., Orlandi, F., Brusamolino, F., Lazzarino, M. and Bernasconi, C. (1985) "Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia" Am. J. Hematol, 20(2), 191-193.
22. Winter, N.J., Variakojis, D., Gaynor, E.R., Larson, R.A. and Miller, K.B. (1985) "Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia", Cancer, 56(3), 443-449.
23. Inbal, A., Januszewicz, E., Rabinowitcz, M. and Shaklai, M. "A therapeutic trial with low-dose cytarabine in myelodysplastic syndromes and acute leukemia", Acta Haematol., 73(2), 71-74.
24. Worsley, A., Mufti, G.J., Copplestone, J.A., Oscier, D.G. and Hamblin, T.J. (1986) "Very-low-dose cytarabine for myelodysplastic syndromes and acute myeloid leukemia in the elderly", Lancet, 1(8487), 966.
25. Mineur, P., Martiat, P., Ferrant, A. and Michaux, J.L. (1989) "Low-dose cytosine arabinoside in myelodysplastic syndromes", Acta Clin. Belg., 44(1), 62-63.
26. Castaigne, S., Tilly, H., Sigaux, F., Solal-Celigny, P., Bordessoule, D., Briere, J., et al. (1985) "Treatment of malignant hemopathies with aracytine in low doses. Analysis of 159 cases", Nouv. Rev. Fr. Hematol., 27(6), 377-382.
27. Kufe, D.W., Spriggs, D.R. and Griffin, D.J. (1987) "Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside", Semin. Oncol., 14(2 Suppl 1), 149-158.
28. Powell, B.L., Capizzi, R.L., Jackson, D.V., Richards, F., Muss, H.B., Lyerly, E.S., et al. (1988) "Low dose Ara-C for patients with myelodysplastic syndromes", Leukemia, 2(3), 153-156.
29. Aul, C. and Schneider, W. (1989) "The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes", Cancer, 64(9), 1812-1818.
30. Hellstrom-Lindberg, E., Robert, K.H., Gahrton, G., Lindberg, G., Forsblom, A.M., Kock, Y., et al. (1992) "A predictive model for the clinical response to low dose Ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukemia", Br. J. Haematol., 81(4), 503-511.
31. Miller, K.B., Kim, K., Morrison, F.S., Winter, J.N., Bennett, J.M., Neiman, R.S., et al. (1992) "The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study", Ann. Hematol., 65(4), 162-8. Erratum in: Ann. Hematol. ,1993, 66(3), 164.
32. Bolwell, B.J., Cassileth, P.A. and Gale, R.P. (1987) "High dose cytarabine: a review", Leukemia, 2(5), 253-260.
33. Ho, A.D, Martin, H., Knauf, W., Reichardt, P., Trumpel, L. and Hunstein, W. (1987) "Combination of low-dose cytarabine and 13-cis-retinoic acid in the treatment of myelodycsplastic syndromes" , Leak. Res., 11, 1041-1046.
34. Clark, R.E., Ismail, S.A.D., Jacobs, A., Payne, H. and Smiths, S.A. (1987) "A randomized trial of 13-cis-retinoic-acid with or without cytosine arabinoside in patients with the myelodisplastic syndromes", Br. J. Hematol., 66, 77-83.
35. Letendre, L., Noel, P., White, W.L., Tefferi, A., Litzow, M.R., Li, C.Y., et al. (1999) "Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C", Leuk. Res., 23(9), 811-815.
36. Kuriya, S., Murai, K., Miyairi, Y., Utsugisawa, T., Narigasawa, Y., Ito, T., et al. (1996) "A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study", Cancer, 78(3), 422-426.
37. Okumura, H., Yoshida, T., Takamatsu, H., Katoh, T., Murashima, M., Watanabe, A., et al. (1997) "Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor", Int. J. Hematol., 65(3), 263-268.
38. Munshi, N.C. and Tricot, G.J. (1997) "Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia", Ann. Hematol., 74(3), 111-115.
39. Venditti, A., Scimo, M.T., del Poeta, G., Buccisano, F., Stasi, R., Mastino, A., et al. (1995) "Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study", Leuk. Lymphoma, 16(3-4), 335-342.
40. Gerhartz, H.H., Marcus, R., Delmer, A., Zwierzina, H., Suciu, S., Dardenne, M., et al. (1994) "A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group", Leukemia, 8(1), 16-23.
41. Fukuhara, T., Miyake, T., Maekawa, I., Kurosawa, M., Suzuki, S., Noto, S., et al. (2000) "Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study", Int. J. Hematol., 71(4), 366-371.
42. Saito, K., Nakamura, Y., Aoyagi, M., Waga, K., Yamamoto, K., Aoyagi, A., et al. (2000) "Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation", Int. J. Hematol., 71(3), 238-244.
43. Lubbert, M., Wijermans, P., Kunzmann, R., Verhoef, G., Bosly, A., Ravoet, C., et al. (2001) "Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine", Br. J. Haematol., 114(2), 349-357.